cmx-001 and DNA-Virus-Infections

Brincidofovir (BCV) is a lipid conjugate of cidofovir with good oral bioavailability, enabling optimal intracellular levels of the active drug. Lower rates of nephrotoxicity and myelotoxicity make it a favorable alternative. Despite a greater safety profile among pediatric hematopoietic cell transplant recipients, the oral formulation has been associated with increased gastrointestinal toxicity in adult hematopoietic cell transplant recipients. Oral BCV continues to be developed as a countermeasure against smallpox, while a potentially safer intravenous preparation has been out licensed to another company. BCV has demonstrated great

Topics: Adenovirus Infections, Human; Animals; Antiviral Agents; Clinical Trials as Topic; Cytosine; DNA Virus Infections; DNA Viruses; Humans; Immunocompromised Host; Organophosphonates

Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in vitro, but clinical experience is limited. Here we report a young female who developed a mixed infection with adenovirus, cytomegalovirus, Epstein-Barr virus and BK polyomavirus after an allogeneic stem cell transplant, and was successfully treated with brincidofovir.

Topics: Adult; Antiviral Agents; BK Virus; Coinfection; Cytomegalovirus; Cytosine; DNA Virus Infections; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Immunocompromised Host; Organophosphonates; Stem Cell Transplantation; Viral Load; Young Adult

CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

Topics: Adenoviridae; Antiviral Agents; Cytomegalovirus; Cytosine; DNA Virus Infections; Humans; Microbial Sensitivity Tests; Molluscum contagiosum virus; Organophosphonates; Orthopoxvirus; Polyomavirus